In an interim analysis Opdivo in CheckMate -274 met primary endpoints of disease-free survival in both all randomized patients and in patients whose tumors express PD-L1 in at least 1% of cells.- BMS
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest